BidaskClub upgraded shares of Kala Pharmaceuticals (NASDAQ:KALA) from a sell rating to a hold rating in a research report report published on Saturday morning.

Several other equities research analysts have also recently commented on the company. Wells Fargo & Co reaffirmed a buy rating on shares of Kala Pharmaceuticals in a report on Friday, January 5th. Wedbush reaffirmed an outperform rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a report on Friday, December 22nd. JPMorgan Chase & Co. set a $35.00 price target on Kala Pharmaceuticals and gave the company a buy rating in a report on Sunday, November 19th. Finally, Zacks Investment Research cut Kala Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Kala Pharmaceuticals has an average rating of Buy and a consensus price target of $36.80.

Shares of Kala Pharmaceuticals (NASDAQ KALA) opened at $16.47 on Friday. Kala Pharmaceuticals has a fifty-two week low of $11.81 and a fifty-two week high of $26.75. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.00 and a quick ratio of 11.00. The company has a market capitalization of $388.97 and a P/E ratio of -9.05.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.14). research analysts forecast that Kala Pharmaceuticals will post -2.22 EPS for the current year.

In related news, major shareholder Orbimed Advisors Llc purchased 170,338 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The stock was purchased at an average price of $12.83 per share, with a total value of $2,185,436.54. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

A number of hedge funds have recently bought and sold shares of the business. Orbimed Advisors LLC acquired a new stake in Kala Pharmaceuticals during the third quarter worth $54,251,000. Caxton Corp acquired a new stake in Kala Pharmaceuticals during the third quarter worth $12,430,000. Victory Capital Management Inc. acquired a new stake in Kala Pharmaceuticals during the third quarter worth $12,414,000. OxFORD Asset Management LLP acquired a new stake in Kala Pharmaceuticals during the third quarter worth $4,374,000. Finally, JPMorgan Chase & Co. acquired a new stake in Kala Pharmaceuticals during the third quarter worth $4,037,000. 62.96% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/01/17/kala-pharmaceuticals-kala-raised-to-hold-at-bidaskclub.html.

Kala Pharmaceuticals Company Profile

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Analyst Recommendations for Kala Pharmaceuticals (NASDAQ:KALA)

Receive News & Stock Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related stocks with our FREE daily email newsletter.